Novozymes A/S
CSE:NSIS B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novozymes A/S
CSE:NSIS B
|
DK |
|
C
|
Clariant AG
LSE:0QJS
|
CH |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
US |
|
Venus Concept Inc
NASDAQ:VERO
|
CA |
|
Semiconductor Manufacturing International Corp
SSE:688981
|
CN |
|
Paladin Energy Ltd
ASX:PDN
|
AU |
|
T
|
TCS Group Holding PLC
F:13T1
|
CY |
|
U
|
Union Pacific Corp
F:UNP
|
US |
|
A
|
AngioDynamics Inc
XBER:UG2
|
US |
|
mBank SA
WSE:MBK
|
PL |
|
Embotelladora Andina SA
F:AKOB
|
CL |
|
Lumax AutoTechnologies Ltd
NSE:LUMAXTECH
|
IN |
|
A
|
Accelerate Diagnostics Inc
LSE:0H8E
|
US |
|
F
|
Fission Uranium Corp
F:2FU
|
CA |
|
NETGEAR Inc
NASDAQ:NTGR
|
US |
|
A
|
AXA SA
DUS:AXA
|
FR |
|
Banco Santander SA
MAD:SAN
|
ES |
|
United Therapeutics Corp
NASDAQ:UTHR
|
US |
|
Grupo Bimbo SAB de CV
OTC:GRBMF
|
MX |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NSIS B's stock price target?
Not Available
NSIS B does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.